Autoantibodies in the disease criteria for systemic sclerosis: The need for specification for optimal application

Mahler, 2020, Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets, Autoimmun. Rev., 19, 10.1016/j.autrev.2020.102583 Masi, 1980, Subcommittee for scleroderma criteria of American rheumatism association diagnostic and therapeutic criteria committee, preliminary criteria for the classification of systemic sclerosis (scleroderma), Arthritis Rheum., 23, 581, 10.1002/art.1780230510 Douvas, 1979, Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma, J. Biol. Chem., 254, 10514, 10.1016/S0021-9258(19)86738-8 LeRoy, 2001, Criteria for the classification of early systemic sclerosis, J. Rheumatol., 28, 1573 Tan, 1989, Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology, Adv. Immunol., 44, 93, 10.1016/S0065-2776(08)60641-0 Koenig, 2008, Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis. A twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis, Arthritis Rheum., 58, 3902, 10.1002/art.24038 van den Hoogen, 2013, Classification criteria for systemic sclerosis. An American College of Rheumatology/European League against rheumatism collaborative initiative, Ann. Rheum. Dis., 72, 1747, 10.1136/annrheumdis-2013-204424 Damoiseaux, 2020, The perspective on standardisation and harmonisation: the viewpoint of the EASI president, AutoImmun, Highlights, 11, 4, 10.1186/s13317-020-0127-3 Hahroum, 2021, The mosaic of autoimmunity – a taste for more. The 12th international congress of autoimmunity 2021 (AUTO12) virtual, Autoimmun. Rev., 20 Reveille, 2003, The American College of Rheumatology Ad Hoc committee on immunologic testing guidelines, evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies, Arthritis Rheum., 49, 399, 10.1002/art.11113 Sobanski, 2014, Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: new data from a French cohort and a systematic review and meta-analysis, Arthritis Rheum., 66, 407, 10.1002/art.38219 Mehra, 2013, Autoantibodies in systemic sclerosis, Autoimmun. Rev., 12, 340, 10.1016/j.autrev.2012.05.011 Didier, 2018, Autoantibodies associated with connective tissue diseases: what meaning for clinicians?, Front. Immunol., 9, 541, 10.3389/fimmu.2018.00541 Fransen, 2012, Items for developing revised classification criteria in systemic sclerosis: results of a consensus exercise, Arthritis Care Res., 64, 351, 10.1002/acr.20679 Johnson, 2012, Validation of potential classification criteria for systemic sclerosis, Arthritis Care Res., 64, 358, 10.1002/acr.20684 Bonroy, 2012, Optimization and diagnostic performance of a single multiparameter lineblot in the serological workup of systemic sclerosis, J. Immunol. Methods, 379, 53, 10.1016/j.jim.2012.03.001 Alkema, 2021, Autoantibody profiles in systemic sclerosis; a comparison of diagnostic tests, Autoimmunity, 54, 148, 10.1080/08916934.2021.1907842 Chan, 2015, Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014-2015, Front. Immunol., 6, 412, 10.3389/fimmu.2015.00412 Damoiseaux, 2019, Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patters (ICAP) perspective, Ann. Rheum. Dis., 78, 879, 10.1136/annrheumdis-2018-214436 von Mühlen, 2021, How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative, Immunol. Res., 69, 594, 10.1007/s12026-021-09233-0 Damoiseaux, 2006, From ANA to ENA: how to proceed?, Autoimmun. Rev., 5, 10, 10.1016/j.autrev.2005.05.007 Vulsteke, 2021, Titre-specific positive predictive value of anti-nuclear antibody patterns, Ann. Rheum. Dis., 80, e128, 10.1136/annrheumdis-2019-216245 Andrade, 2018, On behalf of the Executive Committee of ICAP, International consensus on antinuclear antibody patterns: definition of the AC-29 pattern associated with antibodies to DNA topoisomerase I, Clin. Chem. Lab. Med., 56, 1783, 10.1515/cclm-2018-0188 Solomon, 2002, Evidence-based guidelines for the use of immunogic tests: antinuclear antibody testing, Arthritis Rheum., 47, 434, 10.1002/art.10561 Mahler, 2014, Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies, J. Immunol. Res., 2014, 10.1155/2014/315179 Aringer, 2019, European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus, Ann, Rheum. Dis., 78, 1151, 10.1136/annrheumdis-2018-214819 Bonroy, 2013, The integration of the detection of systemic sclerosis-associated antibodies in a routine laboratory setting: comparison of different strategies, Clin. Chem. Lab. Med., 51, 2151, 10.1515/cclm-2013-0211 Damoiseaux, 2014, Are autoantibodies to RNA-polymerase III to be incorporated in routine diagnostic laboratory algorithms for systemic autoimmune rheumatic diseases?, Ann. Rheum. Dis., 73, e29, 10.1136/annrheumdis-2014-205193 Lundberg, 2017, Ann. Rheum. Dis., 76, 1955, 10.1136/annrheumdis-2017-211468 Fierz, 2021, Likelihood ratio approach and clinical interpretation of laboratory tests, Front. Immunol., 12, 10.3389/fimmu.2021.655262